Immune checkpoint inhibitors (ICIs) for second-line retreatment in esophageal cancer progressing after first-line immunotherapy: a single-center retrospective cohort study
Yixin Kang, Youjia Mi, Ce Zhang, Wenyao Li, Junqiang Yang, Jun Yao, Dianbao Zhang · 2026
Read Immune checkpoint inhibitors (ICIs) for second-line retreatment in esophageal cancer progressing after first-line immunotherapy: a single-center retrospective cohort study by Yixin Kang, Youjia Mi, Ce Zhang, Wenyao Li, Junqiang Yang, Jun Yao, Dianbao Zhang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13655824.txt.
Description
Kang and co-authors look back at patients with cancer of the food pipe whose disease grew worse during a first course of immune therapy. The question was whether giving the same kind of immune drug again, as a second course, could still help. All patients came from one hospital in China.
Each patient had at least three months of the first treatment and at least two rounds of the second. Half of the group lived ten months or more after the second course began. About one third saw their tumors shrink, and about two thirds kept the disease in check for a time. Patients whose first course held the disease for over six months did best. Side effects were manageable, and no deaths were tied to the treatment.
Catalog record
| CREATOR | Yixin Kang, Youjia Mi, Ce Zhang, Wenyao Li, Junqiang Yang, Jun Yao, Dianbao Zhang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 34 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |